Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.
CONCLUSIONS: Eptifibatide, tirofiban, and cangrelor are preferred over abciximab as a perioperative bridge. The choice of agent should be tailored to clinical characteristics of the patient and institutional acquisition costs.
PMID: 30646761 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Van Tuyl JS, Newsome AS, Hollis IB Tags: Ann Pharmacother Source Type: research
More News: Abciximab | Bleeding | Coronary Artery Bypass Graft | Drugs & Pharmacology | Eptifibatide | Integrilin | Study